Kristie L. Kahl

In this week’s episode, we spoke with entertainment journalist Giuliana Rancic, who discussed her breast cancer journey and how, at the end of the day, she continued to tell herself, “This, too, shall pass.”

Diabetes may be a risk factor for increased symptoms among breast cancer survivors, particularly for physical and cognitive function, sleep and fatigue.

Shared decision-making with health care providers can help to implement a comprehensive pain assessment at baseline and improve outcomes among patients with metastatic cancer.

Despite increased physical activity, nutritional intake behavior among female cancer survivors did not improve with an exercise intervention program, according to a randomized-controlled trial.

Researchers found significant gender and role differences regarding cardiovascular disease incidence and its related health behaviors among cancer survivors and their spouses.

According to survey results, almost 30% of non-muscle invasive bladder cancer survivors experienced at least one PTSD symptom.

In this week’s episode, we spoke with the founder and CEO of Savor Health on the importance of nutrition for patients and caregivers before, during and after cancer treatment.

Patients with glioblastoma may lack easy access to clinical trials and off-label treatments, despite showing an interest in learning more about them.

Izidore S. Lossos, M.D., discussed how questions remain on how to find the least toxic therapies that will prolong survival in both young and elderly patients with mantle cell lymphoma.

The Healing Net Foundation gathers patients, caregivers and health care providers to collaborate in raising awareness and educating the medical community about an underserved disease: neuroendocrine tumors.

Although a reasonable and often curative treatment option, use of allogeneic hematopoietic stem cell therapy in relapsed multiple myeloma still tends to fall under the radar.

In this week’s episode, we spoke with wife, mother, comedian and colon cancer survivor Heather Tolley-Bauer about finding comedy as an outlet to her diagnosis.

An expert discusses new treatment options for patients diagnosed with CLL.

Patients with previously treated, advanced NSCLC who received Opdivo therapy experienced a survival benefit over many years, according to a pooled analysis of four studies.

Patients with relapsed or refractory chronic lymphocytic leukemia may have more options now than ever before, according to William G. Wierda, M.D., Ph.D.

While novel agents continue to evolve in the treatment landscape for chronic lymphocytic leukemia, many may start to be combined in the front-line setting as well, according to Matthew S. Davids, M.D., MMSc.

This week, we spoke with all three of CURE’s 2019 Ovarian Cancer Heroes: Ryan Mitstifer Walton, Paula Anastasia, RN, MN, AOCN, and Shannon Westin, M.D., M.P.H.

Barriers to treatment can be an uphill battle for patients with cancer; however, one company is here to help.

Enormous progress has been made in breast cancer, yet many challenges remain, according to Ann H. Partridge, M.D., MPH.

Administration of Opdivo (nivolumab) before surgical resection in patients with glioblastoma appeared safe and feasible, according to phase 2 trial results published in Nature Medicine.

The Food and Drug Administration (FDA) Expanded Access program appeared to have broad use, involved a wide variety of patients and drugs, and derived clinical benefit, according to an initial summary published in JAMA Oncology.

In this week’s episode, we spoke with the most decorated Olympic gymnast and ovarian cancer survivor Shannon Miller before CURE’s second annual Ovarian Cancer Heroes gala.

Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.

Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.

With the evolving landscape of maintenance therapies to treat patients with lymphoma following auto-HCT, a panel consensus recommended four grade A options for physicians to utilize.

In this week’s episode, we spoke with Linda Tantawi about Susan G. Komen Greater New York City, and how the organization is connecting communities to educate women about breast cancer.

A cancer gene panel using blood may be a cost-effective way of testing the quantity of mutations found in tumors of patients with non-small cell lung cancer.